4.00%
-11.65%
-8.61%
-34.06%
-40.52%
-80.22%
-87.74%
AI Spotlight on CTMX
Company Description
CytomX Therapeutics, Inc.operates as an oncology-focused biopharmaceutical company in the United States.The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.
The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor.The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc.
to develop Probody therapeutics.CytomX Therapeutics, Inc.was founded in 2008 and is headquartered in South San Francisco, California.
Market Data
| Last Price | 0.91 |
| Change Percentage | 4.00% |
| Open | 0.88 |
| Previous Close | 0.88 |
| Market Cap ( Millions) | 71 |
| Volume | 74177 |
| Year High | 5.85 |
| Year Low | 0.79 |
| M A 50 | 1.01 |
| M A 200 | 1.37 |
Financial Ratios
| FCF Yield | -124.67% |
| Dividend Yield | 0.00% |
| ROE | -41.34% |
| Debt / Equity | -45.19% |
| Net Debt / EBIDTA | -370.48% |
| Price To Book | -3.3 |
| Price Earnings Ratio | 5.6 |
| Price To FCF | -0.8 |
| Price To sales | 0.56 |
| EV / EBITDA | 5.1 |
News
- Jan -06 - CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
- Dec -16 - CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Nov -27 - CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
- Nov -19 - Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
- Nov -08 - CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript
- Nov -07 - CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates
- Nov -07 - CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Sep -09 - CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
- Aug -08 - CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Jun -18 - CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Jun -17 - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
- Jun -05 - Buy Alert: 3 Penny Stocks That Will Explode in 2024
- May -29 - No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
- May -22 - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
- May -16 - CytomX Therapeutics Announces New Employment Inducement Grants
- May -09 - Why Is CytomX (CTMX) Stock Down 43% Today?
- May -09 - CytomX stock down 30% despite encouraging cancer study results
- May -08 - CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- May -08 - CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- May -07 - CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Probody Therapeutics
Expected Growth : 11.3 %
What the company do ?
Probody Therapeutics is a platform from CytomX Therapeutics, Inc. that uses masked antibodies to target cancer cells, reducing toxicity and improving efficacy.
Why we expect these perspectives ?
Probody Therapeutics' 11.3% growth is driven by increasing adoption in oncology and inflammation, leveraging CytomX's proprietary Probody platform. Strong partnerships, expanding pipeline, and promising clinical trials contribute to growth. Additionally, the rising demand for targeted therapies and increasing investment in R&D fuel the segment's expansion.
Cytomx Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Probody Therapeutics | A platform that utilizes masked antibodies to target cancer cells, reducing toxicity and improving efficacy. |
| CD3 Probody Therapeutics | A subset of Probody Therapeutics that targets CD3, a protein expressed on T cells, to redirect T cell-mediated killing of cancer cells. |
| TCR-Mimic Bispecifics | A type of bispecific antibody that mimics the activity of T cell receptors (TCRs) to target cancer cells. |
| Probody Drug Conjugates | A platform that utilizes Probody technology to deliver cytotoxic payloads directly to cancer cells. |
CytomX Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
CytomX Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
CytomX Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
CytomX Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like CytomX Therapeutics, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established companies competing for market share. CytomX Therapeutics, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | -41.75% |
| Debt Cost | 3.95% |
| Equity Weight | 141.75% |
| Equity Cost | 9.37% |
| WACC | 11.64% |
| Leverage | -29.45% |
CytomX Therapeutics, Inc. : Quality Control
CytomX Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
